Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models

Table 1

Different human studies of fenofibrate on NAFLD/NASH.

Diseases	Dose	Number of subjects	Duration of the intervention	Effect/side effect	Ref
Hypertriglyceridemia and NAFLD	200 mg	53	12 weeks	(i) Increasing: TLF, LV, plasma acetylcarnitine, butyrylcarnitine levels; (ii) Decreasing: serum TG, plasma docosahexaenoic acid	[32]
NAFLD	200 mg fenofibrate per day	90	12 weeks	(i) Decreding: ALT, AST, SBP, DBP, BMI	[7]
NAFLD	300 mg daily	90	24 weeks	(i) No effect on lipid panel; (ii) Beneficial effect on indirect biochemical markers of hepatic fibrosis, (hyaluronic acid), TGF-beta 1; (iii) Beneficial effect on inflammatory pathway; (iv) Beneficial effect on insulin resistance; (v) Beneficial effect on liver stiffness	[30]
NASH	—	124	12 weeks	(i) Improve serum transaminase; (ii) Improve clinical symptoms; (iii) Improve blood lipids	[33]
Obese-NAFLD	200 mg/day	27	8-16 weeks	(i) Increasing: VLDL-TG clearance of plasma; (ii) Decreasing: VLDL-apolipoprotein B secretion; (iii) No rise in VLDL-TG secretion; (iv) No effect on insulin action	[34]
NAFLD	200 mg/day	17	48 weeks	(i) Increasing: ApoA1; (ii) Decreasing: TG, glucose, ALP, GGT; (iii) Without adverse events	[31]

TLF: total liver fat; LV: liver volume; TG: triglyceride; AST: aspartate transaminase; ALT: alanine aminotransferase; VLDL: low-density lipoprotein; ALP: alkaline phosphatase; GGT: γ-glutamyltranspeptidase; ApoA1: apolipoprotein A1.